Lokman Hekim Health Sciences
Article Open Access Volume 6 · Issue 1 · 2026 pp. 150–158

Updates on Aspergillosis in Chronic Granulomatous Disease

Zeynep Ergenç1 ORCID, Adilia Warris2 ORCID
1 Department of Pediatric Infectious Diseases and Immunology, Great Ormond Street Hospital for Children, London, United Kingdom;Vaccine Institute and Centre for Neonatal and Pediatric Infection, City St. George’s, University of London, London, United Kingdom
2 Department of Pediatric Infectious Diseases and Immunology, Great Ormond Street Hospital for Children, London, United Kingdom;Department of Biosciences, Medical Research Centre for Medical Mycology, University of Exeter, Exeter Faculty of Health and Life Sciences, United Kingdom.
Published: 2026 DOI: 10.14744/lhhs.2025.80707 Article ID: LHHS-80707
PDF
Abstract
Patients with Chronic Granulomatous Disease (CGD) face the highest lifelong risk of invasive aspergillosis (IA). Effective management of IA in this population requires meticulous care and a well-coordinated, multidisciplinary approach. This includes primary antifungal prophylaxis, timely evaluation and treatment of suspected IA, and the use of diagnostic methods to make a causative diagnosis. In this review, we aim to assess recent advancements in the diagnosis and treatment of IA in patients with CGD.

Keywords: Aspergillus; Chronic granulomatous disease; Infections; Mycology

Previous article Next article

Article information

1,434 Views
1,358 Downloads
View / Download PDF

Current Issue Vol 6 · Iss 1

Lokman Hekim Health Sciences – Issue cover
Submit manuscript
Most read & early access
Click an article to open abstract.
View all articles